ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
16 announcements with these filters
Medicamen Organics filed auditor certificate for Rs 87.5 lakh warrant balance received from Pradeep Kumar Jain. Warrant conversion allotted 10 lakh equity shares at Rs 35 each.
Medicamen Organics allotted 10,00,000 equity shares on conversion of warrants issued to Mr. Pradeep Kumar Jain. The company received the balance Rs.87.5 lakh, bringing total consideration to Rs.3.50 Crore.
Medicamen Organics held its 31st AGM on September 25, 2026. Shareholders approved audited financial statements, director reappointment, secretarial auditor appointment, and related party transactions.
Medicamen Organics Limited has re-appointed Ms. Divya Rani as the Secretarial Auditor of the company for a period of 12 months.
Medicamen Organics Limited informed shareholders about the web-link to access the Notice of the 31st AGM and Annual Report for FY 2025-26, as per regulatory compliance.
Medicamen Organics Ltd has scheduled its 31st Annual General Meeting for September 25, 2026. The board also approved the re-appointment of its Secretarial Auditors.
Mr. Brijesh Kumar Chaubey has resigned as Executive Director of Medicamen Organics Limited. The resignation is effective July 20, 2026, due to family medical issues.
Medicamen Organics Limited received Rs. 12.29 Crore in consideration for a preferential allotment of equity shares and warrants. The auditor certified compliance with SEBI ICDR Regulations.
Medicamen Organics allotted equity shares and warrants worth ₹13.65 Crore on a preferential basis. This capital infusion strengthens the company's equity base and supports future growth.
Medicamen Organics Limited amended its Code of Practices for Fair Disclosure of Unpublished Price Sensitive Information. This update ensures compliance with current SEBI regulations.
Medicamen Organics reported 15.41% unutilized IPO proceeds, totaling ₹162.44 Lakhs. Shareholders approved reallocating these funds from international product registration to meeting working capital requirements.
Medicamen Organics Ltd reported revenue from operations of ₹4.8 Cr (-77.8% YoY) and a net loss of ₹6.1 Cr for H2 FY26.
Medicamen Organics Limited reported its audited standalone and consolidated financial results for the year ended March 31, 2026. The Board approved the results at a meeting today.
Medicamen Organics Limited is undertaking a ₹13.65 Crore preferential issue of equity shares and warrants. The capital raise includes a loan conversion by a promoter.
Medicamen Organics Limited scheduled a board meeting for May 29, 2026, to approve audited annual financial results. The trading window remains closed until May 31, 2026.
Medicamen Organics published a valuation report from M/s Jhamb & Associates on its website. The report supports shareholder approval for matters in the upcoming Extra-ordinary General Meeting.